TABLE 4.

Radiographic Progression free survival for each time point for interventions that were significant compared to castratepre (shown as odds ratio and 95% confidence intervals).

Time point	Control group	Target	castratepretarget	chempre	castratepreparp	Targetpre	2castratepre	castratepre400ipa	castrateprepd1	castratepre200ipa
3 months	castratepre	6.88 (1.60; 29.64)	4.15 (1.53; 11.25)	2.99 (1.91; 4.68)	2.54 (1.14; 5.63)	×	×	×	×	×
	prednisone	√	√	√	√	√	×	-	-	-
6 months	castratepre	-	×	2.57 (1.71; 3.86)	2.25 (1.16; 4.38)	-	1.62 (1.15; 2.30)	1.73 (1.18; 2.53)	×	×
	prednisone	3.38 (2.45; 4.65)	√	√	√	√	√	√	√	√
12 months	castratepre	-	×	3.74 (2.12; 6.59)	1.98 (1.10; 3.56)	-	1.45 (1.11; 1.89)	1.71 (1.24; 2.36)	×	×
	prednisone	2.01 (1.23; 3.28)	√	√	√	√	√	√	√	√
18 months	castratepre	-	×	2.94 (1.19; 7.26)	×	×	1.52 (1.18; 1.95)	1.58 (1.15; 2.17)	2.64 (1.09; 6.40)	×
	prednisone	×	√	√	√	√	√	√	√	×

Castratepre (Abiraterone or Enzalutamide + prednisone), prednisone, target (cabozantinib), castratepretarget(ipatasertib or tivantinib + abiraterone + predisone), chempre (Docetaxel or Cabazitaxel + prednisone), castratepreparp (Abiraterone or Enzalutamide + prednisone + olaparib), targetpre (buparlisib or Orteronel + prednisone), 2castratepre (Abiraterone and Enzalutamide), castratepre400ipa (abiraterone + prednisone + 400 mg ipatasertib), castrateprepd1 (atezolizumab + enzalutamide + prednisone), castratepre200ipa (abiraterone + prednisone + 200 mg ipatasertib).

√: the treatment on the top is significant compared to the control group on the left; ×: the treatment on the top is not significant compared to the Control group on the left.